Download PDF
Thromb Haemost 1999; 81(05): 701-704
DOI: 10.1055/s-0037-1614557
Rapid Communication
Schattauer GmbH

Predictive Value of Coagulation Markers Concerning Clinical Outcome 90 Days after Anterior Myocardial Infarction

Carl-Erik Dempfle
1   From the University of Heidelberg, Mannheim University Hospital, First Dept. of Medicine, Mannheim, Germany; University of Oslo, Aker University Hospital
,
Frederic Kontny
2   Dept. of Cardiology, Oslo, Norway
,
Ulrich Abildgaard
3   Dept. of Hematology, Oslo, Norway
› Author Affiliations
Further Information

Publication History

Received 06 July 1998

Accepted after revision 18 January 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

To study the predictive value of coagulation markers concerning clinical outcome, prothrombin fragment F1.2 (F1.2), fibrin monomer antigen (FM), D-Dimer (DD), and fibrinogen were measured in plasma samples drawn 2 and 7 days after acute myocardial infarction (AMI) in 314 consecutive patients randomized in a clinical trial of low molecular weight heparin (Dalteparin) (the FRAMI trial). Placebo-treated patients suffering death or new AMI within 90 days had significantly higher levels at day 2 of FM (Enzymun-Test FM), and DD (TINAquant D-dimer) (p = 0.001 and 0.02, respectively), but not F1.2 (Enzygnost F1.2 micro), relative to those without serious clinical events. At day 7 all three coagulation activation markers were significantly higher in patients with subsequent adverse clinical outcome. The Dalteparin group had significantly lower levels of these markers as compared to the placebo group. Left ventricular (LV) thrombus formation was not associated with changes in coagulation activation. However, patients with thrombus had significantly higher fibrinogen levels than those without thrombus (p = 0.004 day 2), independent of treatment group. Thus, markers of coagulation activation may be useful in stratification of patients when estimating risk for adverse clinical outcome after AMI. Furthermore, elevated fibrinogen levels are associated with increased risk of LV thrombus formation.

 

  • References

  • 1 Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes.. N Engl J Med 1992; 326: 287-91.
    CrossrefPubMedGoogle Scholar
  • 2 DiSciascio G, Cowley MJ, Goudreau E, Vetrovec GW, Johnson DE. Histopathologic correlates of unstable ischemic syndromes in patients undergoing directional coronary atherectomy: in vivo evidence of thrombosis, ulceration, and inflammation.. Am Heart J 1994; 128: 419-26.
    CrossrefPubMedGoogle Scholar
  • 3 Kontny F, Dale J, Nesvold A, Lem P, Soberg T. Left ventricular thrombosis and arterial embolism in acute anterior myocardial infarction.. J Intern Med 1993; 233: 139-43.
    CrossrefPubMedGoogle Scholar
  • 4 Kontny F, Dale J, Hegrenaes L, Lem P, Soberg T, Morstol T. Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy.. Eur Heart J 1993; 14: 1489-92.
    CrossrefPubMedGoogle Scholar
  • 5 Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.. J Am Coll Cardiol 1997; 30: 962-9.
    CrossrefPubMedGoogle Scholar
  • 6 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo.. Blood Coagul Fibrinolysis 1993; 4: 97-102.
    CrossrefPubMedGoogle Scholar
  • 7 Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site ‘A’: effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.. Blood Coagul Fibrinolysis 1993; 4: 79-86.
    CrossrefPubMedGoogle Scholar
  • 8 Kario K, Matsuo T, Kabayashi H, Matsuo M, Yamamoto K, Sakurai G, Baba M. Rapid quantitative evaluation of plasma D-dimer levels in thrombotic states using an automated latex photometric immunoassay.. Thromb Res 1992; 66: 179-89.
    CrossrefPubMedGoogle Scholar
  • 9 Adema E, Gebert U. Pooled patient samples as reference material for D-Dimer.. Thromb Res 1995; 80: 85-8.
    CrossrefPubMedGoogle Scholar
  • 10 Matsuda M, Terukina S, Yamazumi K, Maekawa H, Soe G. A monoclonal antibody that recognizes the NH2-terminal conformation of fragment D.. Excerpta medica 1990; 892: 43-8.
    PubMedGoogle Scholar
  • 11 Bruhn HD, Conard J, Mannucci M, Monteagudo J, Pelzer H, Reverter JC, Samama M, Tripodi A, Wagner C. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination.. Thromb Haemost 1992; 68: 413-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Becker U, Bartl K, Wahlefeld AW. A functional photometric assay for plasma fibrinogen.. Thromb Res 1984; 35: 475-84.
    CrossrefPubMedGoogle Scholar
  • 13 Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.. Circulation 1989; 79: 980-9.
    CrossrefPubMedGoogle Scholar
  • 14 Vila V, Reganon E, Aznar J, Lacueva V, Ruano M, Laiz B. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase.. Thromb Res 1990; 57: 783-94.
    CrossrefPubMedGoogle Scholar
  • 15 Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity ofthrombin in unstable coronary artery disease.. Thromb Haemost 1998; 79: 491-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Ardissino D, Merlini PA, Gamba G, Barberis P, Demicheli G, Testa S, Colombi E, Poli A, Fetiveau R, Montemartini C. Thrombin activity and early outcome in unstable angina pectoris.. Circulation 1996; 93: 1634-9.
    CrossrefPubMedGoogle Scholar
  • 17 Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.. Circulation 1996; 94: 2064-71.
    CrossrefPubMedGoogle Scholar
  • 18 Oshima S, Yasue H, Ogawa H, Okumura K, Matsuyama K. Fibrinopeptide A is released into the coronary circulation after coronary spasm.. Circulation 1990; 82: 2222-5.
    CrossrefPubMedGoogle Scholar
  • 19 Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F. et al Transient intermittent lymphocyte activation is responsible for the instability of angina.. Circulation 1992; 86: 790-7.
    CrossrefPubMedGoogle Scholar
  • 20 Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina.. Circulation 1996; 94: 874-7.
    CrossrefPubMedGoogle Scholar
  • 21 Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG.. I s diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease.. Int J Cardiol 1995; 50:: 31-42.
    CrossrefPubMedGoogle Scholar